Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies
- PMID: 26857811
- DOI: 10.1111/add.13339
Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies
Abstract
Aims: To test if polysubstance use profiles and drug-related outcomes differ between those receiving and not receiving opioid substitution therapies (OST) among people who inject drugs (PWID).
Design: An annual cross-sectional, sentinel sample of PWID across Australia.
Setting: Data came from 3 years (2011-13) of the Illicit Drug Reporting System (IDRS).
Participants: A total of 2673 participants who injected drugs from the combined national IDRS samples of 2011 (n = 868), 2012 (n = 922) and 2013 (n = 883).
Measurements: Latent class analysis (LCA) was used to summarize participants' self-reported use of 18 types of substances, with the resulting polysubstance use profiles then associated with participant experience of a number of drug-related outcomes.
Findings: Polysubstance use profiles exhibiting a broad range of substance use were generally at increased risk of negative drug-related outcomes, whether or not participants were receiving OST, including thrombosis among OST receivers [odds ratio (OR) = 2.13, 95% confidence intervals (CI) = 1.09-4.17], injecting with used needles among OST receivers and non-receivers, respectively (OR = 2.78, 95% CI = 1.50-5.13; OR = 2.15, 95% CI = 1.34-3.45) and violent criminal offences among OST receivers and non-receivers, respectively (OR =2.30, 95% CI = 1.16-4.58; OR = 1.87, 95% CI = 1.14-3.07). An important exception was non-fatal overdose which was related specifically to a class of PWID who were not receiving OST and used morphine frequently (OR = 1.83, 95% CI = 1.06-3.17) CONCLUSION: Regardless of opioid substitution therapies usage, people who inject drugs who use a broad-range of substances experience greater levels of injecting-related injuries and poorer health outcomes and are more likely to engage in criminal activity than other groups of people who inject drugs.
Keywords: Drug treatment; latent class analysis; polysubstance use.
© 2016 Society for the Study of Addiction.
Comment in
-
Commentary on Betts et al. (2016): Polysubstance use and opioid substitution therapy among people who inject drugs.Addiction. 2016 Jul;111(7):1224-5. doi: 10.1111/add.13417. Addiction. 2016. PMID: 27273387 No abstract available.
Similar articles
-
Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.Addiction. 2021 Mar;116(3):525-535. doi: 10.1111/add.15168. Epub 2020 Jul 14. Addiction. 2021. PMID: 32557931
-
The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.J Subst Abuse Treat. 2015 Nov;58:90-4. doi: 10.1016/j.jsat.2015.06.008. Epub 2015 Jun 17. J Subst Abuse Treat. 2015. PMID: 26117080
-
Can differences in the type, nature or amount of polysubstance use explain the increased risk of non-fatal overdose among psychologically distressed people who inject drugs?Drug Alcohol Depend. 2015 Sep 1;154:76-84. doi: 10.1016/j.drugalcdep.2015.06.020. Epub 2015 Jun 22. Drug Alcohol Depend. 2015. PMID: 26130335
-
Direct-acting antiviral treatment for hepatitis C among people who use or inject drugs: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol. 2018 Nov;3(11):754-767. doi: 10.1016/S2468-1253(18)30304-2. Epub 2018 Sep 21. Lancet Gastroenterol Hepatol. 2018. PMID: 30245064
-
Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematic review.PLoS Med. 2019 Dec 31;16(12):e1003002. doi: 10.1371/journal.pmed.1003002. eCollection 2019 Dec. PLoS Med. 2019. PMID: 31891578 Free PMC article.
Cited by
-
Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder.Harm Reduct J. 2023 Dec 2;20(1):173. doi: 10.1186/s12954-023-00906-7. Harm Reduct J. 2023. PMID: 38042801 Free PMC article. Clinical Trial.
-
Patterns of polysubstance use and clinical comorbidity among persons seeking substance use treatment: An observational study.J Subst Use Addict Treat. 2023 Mar;146:208932. doi: 10.1016/j.josat.2022.208932. Epub 2023 Jan 7. J Subst Use Addict Treat. 2023. PMID: 36880895 Free PMC article.
-
Longitudinal polysubstance use patterns and non-fatal overdose: A repeated measures latent class analysis.Int J Drug Policy. 2025 Jul;141:104301. doi: 10.1016/j.drugpo.2023.104301. Epub 2024 Jan 5. Int J Drug Policy. 2025. PMID: 38182524
-
Relationship between opioid cross-tolerance during buprenorphine stabilization and return to opioid use during buprenorphine dose tapering.Psychopharmacology (Berl). 2024 Jun;241(6):1151-1160. doi: 10.1007/s00213-024-06549-1. Epub 2024 Feb 8. Psychopharmacology (Berl). 2024. PMID: 38326506 Clinical Trial.
-
Opioid and Polydrug Use Among Patients in Opioid Maintenance Treatment.Subst Abuse Rehabil. 2020 Jan 29;11:9-18. doi: 10.2147/SAR.S221618. eCollection 2020. Subst Abuse Rehabil. 2020. PMID: 32099510 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials